Compare DexCom, Inc. (DXCM) vs Fiverr International Ltd (FVRR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Fiverr International Ltd — how do they compare? DexCom, Inc. trades at $84.11 (market cap $31.86B), while Fiverr International Ltd trades at $8.72 (market cap $310.61M). The key difference: DexCom, Inc. is far larger — about 102.6× Fiverr International Ltd's market cap, and DexCom, Inc. is trading nearer its 52-week high, Fiverr International Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Fiverr International Ltd for 62 Days on average.
| DXCM | FVRR | |
|---|---|---|
Market Cap | $31.86B | $310.61M |
Volume | 3,607,070 | 381,459 |
Sector | Health | Media |
52-Week High | $92.34 | $23.60 |
52-Week Low | $54.84 | $8.47 |
Typical Hold Time | 62 Days | 62 Days |
Enterprise Value | $31.32B | $63.00M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.41, showing modest daily gains of 0.13%. The stock demonstrates strong fundamental performance with consistent earnings beats and robust revenue growth, reaching $4.66 billion in 2025. Technical indicators show a bearish short-term trend with key support at $82. The company maintains impressive profitability with 20.12% net margins and 38.49% ROE, supported by growing adoption of CGM technology in diabetes care.
DXCM presents a compelling growth story with expanding market opportunities in Type 2 diabetes care. Analyst consensus remains strongly bullish with 81% buy ratings and $95.07 price target, suggesting 13% upside. Key risks include reimbursement challenges and competitive pressures. The company's strong cash flow generation and institutional support provide solid foundation for continued growth.
Fiverr International (FVRR) trades at $8.64, up 1.65% on the day, amid a bearish technical outlook with recent earnings misses in Q1 and Q2 2026. Revenue for 2025 reached $430.91M with a net income margin of 7.18%, though 2026 revenue is projected to dip to $418M. Valuation ratios appear attractive with a P/E of 10.67 and P/S of 0.76, but the stock faces headwinds from AI disruption compressing demand for freelance services, as highlighted in recent news.
The stock's outlook is cautious, with analyst consensus leaning Hold (76.47%) and a price target of $10.50 offering potential upside. Key risks include AI-driven market shifts and competitive pressures, while the current low valuation may appeal to value investors if the company navigates transitional challenges successfully.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Fiverr International Ltd
Fiverr International Ltd is involved in buying and selling digital services in the same fashion as physical goods on an e-commerce platform. It is set out to design a digital marketplace that is built with a comprehensive SKU-like services catalog and a search, finds, and order process that mirrors a typical e-commerce transaction. The service offerings of the company include Graphics and Design, Digital Marketing, Writing and Translation, and Video and Animation among others.
Read more on FVRR →
